Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multimodality Therapy in HER-2+ Stage IIIA, IIIB or Regional Stage IV Breast Cancer
NCT00016276Phase 3Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2001
- Primary completion
- Mar 2005
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dexrazoxane and trastuzumab in breast cancer (8 arms), sponsored by National Cancer Institute. Primary endpoints: Median number of positive axillary lymph nodes at 24 weeks, Pathologic complete response rate in the breast and axilla at 24 weeks and 2 more. Started May 2001; status: terminated.
02
Drugs
dexrazoxanetrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00016276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016276.